Diagnostic value of tumor m2-pyruvate kinase level in lung cancer and its relationship with tumor histological type

Abstract

Aims: To investigate the diagnostic value of purivate kinase isoenzyme-M2 (M2-PK) levels and their relationship with tumor histological type in patients diagnosed with lung cancer. Methods: In this prospective study, 98 cases diagnosed with lung cancer (Study group) and 90 cases with lung cancer excluded (Control group) were included. The study group consisted of people over the age of 18 who had been diagnosed with lung cancer and had not received any treatment for the tumor. The control group consisted of 45 people who had been diagnosed with any lung disease but did not have lung cancer, and 45 of them were completely healthy people. Those with benign lung disease apart from lung cancer were named as control group-1 and healthy control group was named as control-group-2. Plasma samples with 5 cc of EDTA were taken from all subjects and these samples were quickly frozen at – 80 degrees and stored in this way until laboratory analysis could be performed. Commercial kit based on the sandwich ELISA principle (ScheBo Biotech Ag, Tumor M2-PK ELISA kit, Germany) was used to determine plasma M2-PK levels. The M2-PK values of the samples were calculated on the basis of the standard graph. Results: M2-PK levels were measured and compared in the lung cancer group, control group-1 with non-lung cancer lung disease and healthy control group-2. M2-PK levels were found to be significantly higher in the lung cancer group than in the control group-1 (p<0.0001) and control-group-2 (p<0.0001). When M2-PK levels were compared in all three groups, they were statistically significant in the lung cancer group (p<0.001). In our study, the diagnostic cut off value was found to be 8.9 IU/ml using ROC curve. At this cut-off value, plasma m2-pk level was calculated as 100% sensitivity and 97.8% specificity in showing lung cancer. When compared, there was no statistically significant difference between histopathological diagnoses, stage of the disease and M2-PK levels in the lung cancer group. Conclusion: As a result of this study, it has been shown that tumor M2-PK can be used in the differentiation of lung cancers from other benign lung lesions and as a marker in patients with suspected lung cancer.